Physician profile
Roxy J Sheffield
NPI 1831456409
$7,921.58
in general payments reported to CMS, 2019-2025
48 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,677 · 2022: $1,541 · 2023: $1,428 · 2024: $1,959 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,638 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,637.56 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,291.21 | 2021-2025 | |
| Novo Nordisk INC | $958.84 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $554.57 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $420.41 | 2021-2025 | |
| Boston Scientific Corporation | $368.68 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Amgen INC. | $276.00 | 2021-2025 | Repatha, Otezla, Prolia |
| Otsuka America Pharmaceutical, INC. | $231.85 | 2021-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $218.24 | 2021 | |
| Astellas Pharma US INC | $191.02 | 2021-2025 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $179.61 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $166.95 | 2024-2025 | Auvelity, Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.27 | 2021-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $155.97 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $143.18 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $141.37 | 2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxy Sheffield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.